Trials / Not Yet Recruiting
Not Yet RecruitingNCT06485232
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system. This study aims to evaluate the safety and efficacy of the treatment with universal BCMA and CD19 CART.
Conditions
- Neuromyelitis Optica Spectrum Disorders
- Myasthenia Gravis, Generalized
- Multiple Sclerosis
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Universal BCMA CAR-T | Universal BCMA CAR-T |
| DRUG | Universal CD19 CAR-T | Universal CD19 CAR-T |
| DRUG | Universal BCMA CAR-T; Universal CD19 CAR-T | Universal BCMA CAR-T; Universal CD19 CAR-T |
Timeline
- Start date
- 2025-02-28
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2024-07-03
- Last updated
- 2025-01-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06485232. Inclusion in this directory is not an endorsement.